Novartis Launches Tech Prize to Address Unmet MS Community Needs
Novartis-along with WIRED Brand Lab and other collaborators including Techstars, Shift.ms, and the National Multiple Sclerosis Society-has launched the Innovation Prize for Assistive Tech to encourage new technologies that address the unmet needs of the multiple sclerosis community. The Novartis Innovation Prize: Assistive Tech for Multiple Sclerosis (MS) identifies and embraces technology that aims to improve mobility and daily life for people living with MS. Applications are open worldwide to the tech community, innovators, design experts, patient advocates – "anyone with an idea to make everyday life better for those with MS or mobility-limiting disabilities." Applications will be accepted until January 10, 2020 at 17:00 ET and the winners will be announced at the SXSW conference in Austin, Texas on March 13, 2020. In order to develop their innovation, the first-place winner will receive a prize worth $250,000 and the second-place winner will receive $50,000.* *More information can be found at www.wired.com/msinnovationprize
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Pfizer, GSK Gain ACIP Recommendations for RSV and Meningococcal Vaccines
April 18th 2025The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to Pfizer’s respiratory syncytial virus vaccine Abrysvo for high-risk adults in their 50s and voted in favor of GSK’s meningococcal vaccine, Penmenvy, for streamlined adolescent protection.
